BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20807231)

  • 1. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.
    Chung Y; Law S; Kwong DL; Luk JM
    Dis Esophagus; 2011 Jan; 24(1):49-55. PubMed ID: 20807231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.
    Tian R; Zhang F; Sun P; Wu J; Yan H; Wu AR; Zhang M; Jiang YL; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
    Oncotarget; 2016 Oct; 7(41):67485-67494. PubMed ID: 27528228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
    Ji WH; Jiang YH; Ji YL; Li B; Mao WM
    Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
    Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of
    Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
    World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases.
    J Am Coll Surg; 2001 Jun; 192(6):708-18. PubMed ID: 11400964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
    Jiao XL; Chen D; Wang JG; Zhang KJ
    Eur Rev Med Pharmacol Sci; 2014; 18(4):509-15. PubMed ID: 24610617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma.
    Zhang D; Zhou X; Bao W; Chen Y; Cheng L; Qiu G; Sheng L; Ji Y; Du X
    Oncotarget; 2015 Nov; 6(35):38410-20. PubMed ID: 26334098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
    Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
    Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy.
    Chen YF; Li Q; Chen DT; Pan JH; Chen YH; Wen ZS; Zeng WA
    Cancer Biomark; 2016 Jun; 17(1):89-96. PubMed ID: 27314297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.
    Otowa Y; Nakamura T; Takiguchi G; Tomono A; Yamamoto M; Kanaji S; Imanishi T; Suzuki S; Tanaka K; Itoh T; Kakeji Y
    Dis Esophagus; 2016; 29(2):146-51. PubMed ID: 25515972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cumulative score based on preoperative plasma fibrinogen and serum C-reactive protein could predict long-term survival for esophageal squamous cell carcinoma.
    Tian R; Yan H; Zhang F; Sun P; Wu AR; Zhang M; Jiang YL; Wu J; Lu YH; Xu QY; Zhan XH; Zhang RX; Qian LT; He J
    Oncotarget; 2016 Sep; 7(38):61533-61543. PubMed ID: 27517497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma.
    Hsu PK; Huang CS; Wang BY; Wu YC; Hsu WH
    Ann Thorac Surg; 2014 May; 97(5):1734-41. PubMed ID: 24612702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
    Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
    Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy.
    Aiko S; Yoshizumi Y; Ishizuka T; Sakano T; Kumano I; Sugiura Y; Maehara T
    Dis Esophagus; 2007; 20(2):94-101. PubMed ID: 17439591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.